Free Trial
NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

Allakos logo
$0.33 0.00 (0.00%)
As of 05/15/2025

About Allakos Stock (NASDAQ:ALLK)

Key Stats

Today's Range
$0.33
$0.33
50-Day Range
$0.33
$0.33
52-Week Range
$0.22
$1.56
Volume
N/A
Average Volume
1.20 million shs
Market Capitalization
$29.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Hold

Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ALLK MarketRank™: 

Allakos scored higher than 56% of companies evaluated by MarketBeat, and ranked 484th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Allakos has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Allakos has received no research coverage in the past 90 days.

  • Read more about Allakos' stock forecast and price target.
  • Earnings Growth

    Earnings for Allakos are expected to grow in the coming year, from ($1.17) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Allakos has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Allakos' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ALLK.
  • Dividend Yield

    Allakos does not currently pay a dividend.

  • Dividend Growth

    Allakos does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ALLK.
  • Search Interest

    Only 1 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allakos insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Allakos' insider trading history.
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Allakos And 2 Other Promising Penny Stocks To Watch
Trump set to Boost Social Security Checks by 400%?
If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.
Allakos to Be Acquired for 33 Cents a Share
See More Headlines

ALLK Stock Analysis - Frequently Asked Questions

Allakos' stock was trading at $1.21 at the beginning of the year. Since then, ALLK stock has decreased by 72.8% and is now trading at $0.3291.
View the best growth stocks for 2025 here
.

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01.

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/06/2024
Today
7/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$3.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+507.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$185.70 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.93 per share
Price / Book
0.17

Miscellaneous

Free Float
74,942,000
Market Cap
$29.74 million
Optionable
Optionable
Beta
0.15
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ALLK) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners